Benefits of monitoring patients with mobile cardiac telemetry (MCT) compared with the Event or Holter monitors.

INTRODUCTION: This research is meant to establish if a patient monitored with mobile cardiac telemetry (MCT) sees different outcomes regarding diagnostic yield of arrhythmia, therapeutic management through the use of antiarrhythmic drugs, and cardiovascular costs incurred in the hospital setting when compared with more traditional monitoring devices, such as the Holter or the Event monitor.
MATERIALS AND METHODS: We conducted a retrospective analysis spanning 57 months of claims data from January 2007 to September 2011 pertaining to 200,000+ patients, of whom 14,000 used MCT only, 54,000 an Event monitor only, and 163,000 a Holter monitor only. Those claims came from the Truven database, an employer database that counts 2.8 million cardiovascular patients from an insured population of about 10 million members. We employed a pair-wise pre/post test-control methodology, and ensured that control patients were similar to test patients along the following dimensions: age, geographic location, type of cardiovascular diagnosis both in the inpatient and outpatient settings, and the cardiovascular drug class the patient uses.
RESULTS: First, the diagnostic yield of patients monitored with MCT is 61%, that is significantly higher than that of patients that use the Event monitor (23%) or the Holter monitor (24%). Second, patients naive to antiarrhythmic drugs initiate drug therapy after monitoring at the following rates: 61% for patients that use MCT compared with 39% for patients that use the Event and 43% for patients that use the Holter. Third, there are very significant inpatient cardiovascular savings (in the tens of thousands of dollars) for patients that undergo ablation, coronary artery bypass graft (CABG) and valve septa. Savings are more modest but nonetheless significant when it comes to the heart/pericardium procedure.
CONCLUSION: Given the superior outcome of MCT regarding both patient care and hospital savings, hospitals only stand to gain by enforcing protocols that favor the MCT system over the Event or the Holter monitor.

Introduction

The mobile cardiac telemetry (MCT) system is a small sensor and monitor that patients wear as they go about their daily lives. Whenever cardiac events occur, MCT instantaneously transmits the data to a center for analysis and response, which in turn sends a report along with graphs and trends to the patient’s physician for diagnosis and therapy management.1,2 Given the convenience of the device and its ability to identify arrhythmia cases that other devices miss (thanks to its superior ability to analyze the morphology of the electrocardiogram [EKG/ECG]), the expectation was immediate adoption.3

This is not what happened though. Instead, patients continued to use the Holter and Event monitors. Both are small portable devices that the patient wears. The difference between the Holter and the Event is that the Holter records the patient’s EKG for 24–48 hours, while the Event records the EKG at certain times only and typically for a 30-day period.

Understandably, several payers responded by asking for hard evidence that indicates that the use of MCT indeed leads to better outcomes before they are to adopt MCT. Several studies were undertaken to explain from a clinical standpoint how MCT leads to better outcomes. Unfortunately, those studies ran into challenges, and could not convincingly demonstrate causality.4–7

Is MCT not widely adopted just because studies fail to prove its effectiveness?8 To elucidate the matter, we decided to conduct an observational study that differed from previous ones in one respect. Instead of focusing on explaining causality, this study set out to establish if patients that use MCT indeed have better outcomes. The rationale that links the two was deliberately regarded as out of scope, otherwise this study would be fraught with the same issues that overwhelmed the previous ones.

Materials and methods

We conducted three analyses to assess the impact of usage of MCT on 1) diagnostic yield of arrhythmia, 2) management of arrhythmia through the use of antiarrhythmic drugs, and 3) cardiovascular costs incurred in the inpatient setting.9–11 Table 1 shows the profile of the patients that use MCT, Event, and Holter monitors.

Table 1

Demographic information of patients using MCT, Event, and Holter monitors

Sex: age	Midwest	Northeast	South	West	Total
Females:<40 years	0.7%	0.4%	1.1%	0.4%	2.5%
Males:<40 years	2.2%	1.1%	4.4%	1.2%	8.9%
Females:<40 years 40–65 years	4.6%	2.1%	7.3%	2.2%	16.1%
Males:40–65 years	5.9%	2.4%	10.7%	3.0%	22.0%
Females:>65 years	10.9%	2.9%	7.3%	3.8%	24.9%
Males:>65 years	11.0%	2.9%	7.7%	3.9%	25.6%
Total	35.3%	11.8%	38.4%	14.5%	100%

Abbreviation: MCT, mobile cardiac telemetry.

Analysis 1: diagnostic yield

In this analysis, the patient had to meet the following conditions:

used only one cardiac-monitoring device (MCT or Holter or Event monitor)

used the cardiac-monitoring device 12 months after the start of the database and 12 months before the end of the database

had no arrhythmic International Classification of Diseases (ICD-9) diagnosis code prior to using the cardiac-monitoring device.

We then used for each of the three populations: 1) number of patients in the population (none had an arrhythmia diagnosis prior to the use of the cardiac-monitoring device), and 2) number of patients within the previous group that had an arrhythmic ICD-9 diagnosis code after use of the cardiac-monitoring device. We then computed the diagnostic yield as the ratio of 2 to 1.

Analysis 2: antiarrhythmic drug management

This analysis is similar to the previous one. The patient had to meet the following conditions:

used only one cardiac-monitoring device (MCT or Holter or Event monitor)

used the cardiac-monitoring device 12 months after the start of the database and 12 months before the end of the database

had no arrhythmic diagnosis ICD-9 code prior to the cardiac monitoring device

[new] used no antiarrhythmic drug prior to the cardiac-monitoring device.

We then used for each of the three populations: 1) number of patients in the population (none had an arrhythmia diagnosis or took an antiarrhythmic drug prior to the cardiac-monitoring device), and 2) number of patients within the previous group that took an antiarrhythmic drug after the use of the cardiac-monitoring device. We then computed the antiarrhythmic drug usage as the ratio of 2 to 1.

Analysis 3: cost savings in the hospital setting

The control patients had to meet the following conditions (there were two groups: one for the Holter and the other for the Event monitor):

used only one cardiac-monitoring device (Holter or Event monitor) and did so once

used the Holter or Event monitor 12 months after the start of the database and 12 months before the end of the database.

For pairing to happen, both the test and control patients had to meet the following conditions:

were either younger or older than 65 years, to factor in Medicare

came from the same type of Medicaid state: Medicaid-expansion states (CT and MA), on-track Medicaid states (AZ, DE, ME, MN, NY, PA, WA WI, HI, DC), or Medicaid-challenged states (rest of the US), to factor in dual eligibles whose access to MCT was subject to Medicaid state rules

had the same diagnosis, as defined by the following eight diagnosis groups: acute coronary syndrome, stroke/transient ischemic attack, heart failure, arrhythmia, coronary artery disease, peripheral artery disease, hypertension, and other cardiovascular conditions

used the same drug(s), as defined by the following four drug classes: anti-platelet, antiarrhythmic, anticoagulant, and antihyperlipidemic

used inpatient cardiovascular resources to comparable levels before the cardiac monitor.

We then conducted the following measurements. First, we compared MCT patients with paired-up Holter patients, and second with paired-up Event monitor patients. In both cases, we defined the following: 1) increase in cardiovascular expenses of MCT patients as the difference in cardiovascular costs incurred in the 12 months that followed MCT (post-period) and the cardiovascular costs incurred in the 12 months before MCT (pre-period), 2) the corresponding per-patient difference of the matched control patients to the test patient, 3) the savings due to MCT compared with the other cardiac monitor as the difference between 1 and 2.

We chose a pair-wise test–control approach to allow for the fact that MCT patients may not be a homogeneous group and large differences between patients may occur. Also, we paired each test not with one but with five controls to minimize the vagaries of pairing.

We also conducted additional analyses to refute the following objections:

savings are artificially low because of the way the pairing is done; indeed, costs incurred for the MCT patient are low because the patient is from a low consumer price index (CPI) geography, while the costs incurred for the other cardiac monitoring device are high because the patient is from a high CPI geography

MCT does not lead to any savings, what is happening is simply that costs are still incurred but delayed until the second year following MCT, which the test–control approach fails to pick up on as its postperiod ends before the significant costs are incurred.

In the first case, we reran the analysis by imposing the condition that both test and control patients be from the same geography. The results barely changed, knocking out the CPI argument. In the second case, we reran the analysis, extending the postperiod to 24 months. Once again, the results barely changed, undercutting the basis for the delay argument.

Results

Table 2 indicates that 61% of patients that use MCT are diagnosed with arrhythmia subsequent to the use of the monitor. This is to be compared with 23% for those that use an Event monitor and 24% for those that use a Holter monitor. A Z-test for the difference between two sample proportions (MCT versus Event) revealed that the proportion of patients diagnosed with arrhythmia was 36% higher when the monitor was MCT instead of an Event (P=0.0006). The result was virtually unchanged (35% instead of 36%) when MCT was compared with the Holter (P=0.0006).

Table 2

Patients diagnosed with arrhythmia when using MCT, Event, and Holter monitors

	n	Diagnosed	Difference	P-value
MCT	5,129	61.3%
Event	24,023	23.0%	36%	0.0006
Holter	57,143	24.2%	35%	0.0006

Abbreviation: MCT, mobile cardiac telemetry.

Table 3 indicates that 61% of patients that use MCT are diagnosed with arrhythmia and treated for the first time with an antiarrhythmic drug subsequent to the use of the monitor. This is to be compared with 39% for those that use an Event monitor and 43% for those that use a Holter monitor. A Z-test for the difference between two sample proportions (MCT versus Event monitor) revealed that the proportion of patients diagnosed with arrhythmia and treated for the first time with an antiarrhythmic drug was 20% higher when the monitor was MCT instead of an Event (P=0.0033). The difference dropped just slightly to 16% when MCT was compared with the Holter (P=0.0018).

Table 3

Patients treated with antiarrhythmic drugs when using MCT, Event, and Holter monitors

	n	Treated	Difference	P-value
MCT	5,005	61.1%
Event	22,078	39.0%	20%	0.0033
Holter	52,097	43.0%	16%	0.0018

Abbreviation: MCT, mobile cardiac telemetry.

Table 4 is a summary of the cardiovascular savings (in US$) incurred in the hospital when the patient used the MCT instead of the Event or Holter monitor when undergoing different types of surgeries. Those savings were registered in the 12 months that followed the use of the cardiac-monitoring device. All the sample sizes were larger than 30 and the P-value less than 0.05. The only cases not reported were for patients undergoing a coronary artery bypass graft (CABG) using MCT instead of an Event monitor, and that was because the sample size was only twelve (although savings were very significant US$150,000, with a P-value of 0.0299).

Table 4

Savings when using MCT: ablation, CABG, heart/pericardium, and valve/septa procedures

	MCT vs Event			MCT vs Holter
	Savings (US$)	n	P-value	Savings (US$)	n	P-value
Ablation	35,114	54	<0.0001	36,115	45	<0.0001
CABG				41,700	32	0.0003
Heart/pericardium	17,131	43	0.0281	8,606	54	0.0003
Valve/septa	58,362	35	0.0422	55,390	46	0.0003

Abbreviations: MCT, mobile cardiac telemetry; CABG, coronary artery bypass graft; vs, versus.

Let us take a closer look at each of the four procedures discussed in Table 4. In the case of ablation, MCT led to savings of US$35,114 (P<0.0001) in inpatient cardiovascular costs over the 12 months that followed the use of the device compared with the Event monitor and US$36,115 (P<0.0001) compared with the Holter. (Table 5).

Table 5

Savings (US$) when using MCT – ablation

	Device	Pre-	Post-	Difference	P-value
MCT vs Event (n=54)
Test	MCT	16,132	10,376	(5,756)
Control	Event	6,043	35,400	29,358
Impact				(35,114)	<0.0001
MCT vs Holter (n=45)
Test	MCT	17,996	8,485	(9,511)
Control	Holter	2,759	29,362	26,604
Impact				(36,115)	<0.0001

Abbreviations: MCT, mobile cardiac telemetry; vs, versus.

In the case of CABG procedures, MCT led to savings of US$41,700 (P=0.0003) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Holter. (Table 6).

Table 6

Savings (US$) when using MCT – CABG

	MCT vs Holter (n=32)
	Device	Pre-	Post-	Difference	P-value
Test	MCT	28,508	17,820	(10,688)
Control	Holter	8,960	39,972	31,012
Impact				(41,700)	0.0003

Abbreviations: MCT, mobile cardiac telemetry; CABG, coronary artery bypass graft; vs, versus.

In the case of heart/pericardium procedures, MCT led to savings of US$17,131 (P=0.0281) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Event monitor and US$8,606 (P=0.0003) compared with the Holter. (Table 7).

Table 7

Savings (US$) when using MCT – heart/pericardium procedures

	Device	Pre-	Post-	Difference	P-value
MCT vs Event (n=43)
Test	MCT	11,227	15,470	4,243
Control	Event	2,961	24,334	21,374
Impact				(17,131)	0.0281
MCT vs Holter (n=54)
Test	MCT	6,010	8,065	2,055
Control	Holter	1,016	11,677	10,661
Impact				(8,606)	0.0003

Abbreviations: MCT, mobile cardiac telemetry; vs, versus.

In the case of valve/septa procedures, MCT led to savings of US$58,362 (P=0.0422) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Event monitor and US$55,390 (P=0.0003) compared with the Holter (Table 8).

Table 8

Savings (US$) when using MCT – valve/septa procedures

	Device	Pre-	Post-	Difference	P-value
MCT vs Event (n=35)
Test	MCT	55,624	86,291	30,667
Control	Event	23,345	112,374	89,029
Impact				(58,362)	0.0422
MCT vs Holter (n=46)
Test	MCT	30,429	42,436	12,007
Control	Holter	10,912	78,308	67,397
Impact				(55,390)	0.0003

Abbreviations: MCT, mobile cardiac telemetry; vs, versus.

Discussion

While there certainly is a good rationale, albeit subtle, as to why use of MCT leads to better patient outcomes, offering an explanation will displace the focus of the discussion to a more controversial area, resulting in the expectation that consensus needs to be reached before any action is to be taken. That is the trap to avoid, so we will refrain from offering any explanation.

Faced with the evidence uncovered here, why would a hospital still be better off not to adopt MCT? For one, it may be the case that MCT generates a significant number of false positives, which the Holter or Event monitors do not, leading the hospital to incur unnecessary treatment costs. But that concern has no merit, as MCT uses a morphology-based diagnosis algorithm that only reports problems that are present in the EKG. Besides, the costs of the MCT, Holter, and Event monitors are very comparable and very small in the larger scheme of things. For another, the hospital may not be convinced of the rationale that underpins the usage of MCT and better patient outcomes. But is that in the best interest of the patients?

Conclusion

Our findings can be summed up as follows: use of MCT instead of an Event or a Holter monitor leads to better outcomes regarding diagnostic yield, management of arrhythmia through the use of antiarrhythmic drugs, and cost savings in the hospital for ablation, CABG, heart/pericardium, and valve/septa procedures.

In the unlikely event that MCT does not offer the benefits discussed, adopting MCT in lieu of Holter or Event monitors will not make the hospital worse off. But if, as we presented, MCT does offer the benefits discussed, then adopting MCT is clearly the superior choice. It is then clear that the optimal decision for the hospital is unambiguous: adopt MCT without any further delay.